Monali Vasekar

413 total citations
30 papers, 286 citations indexed

About

Monali Vasekar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Monali Vasekar has authored 30 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 9 papers in Surgery. Recurrent topics in Monali Vasekar's work include Bladder and Urothelial Cancer Treatments (8 papers), Renal cell carcinoma treatment (4 papers) and Epigenetics and DNA Methylation (4 papers). Monali Vasekar is often cited by papers focused on Bladder and Urothelial Cancer Treatments (8 papers), Renal cell carcinoma treatment (4 papers) and Epigenetics and DNA Methylation (4 papers). Monali Vasekar collaborates with scholars based in United States, Netherlands and Denmark. Monali Vasekar's co-authors include Monika Joshi, David J. DeGraff, Timothy Craig, Joseph J. Drabick, Sumanta K. Pal, Hong Zheng, Hamid Emamekhoo, Xin Liu, Kent E. Vrana and Syed Rizvi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Monali Vasekar

23 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Monali Vasekar United States 8 122 97 76 69 64 30 286
Tomoyuki Sasaki Japan 8 108 0.9× 35 0.4× 81 1.1× 76 1.1× 35 0.5× 16 268
Keiko Kagami Japan 11 80 0.7× 60 0.6× 130 1.7× 78 1.1× 55 0.9× 37 379
Kengo Nakahata Japan 11 88 0.7× 149 1.5× 94 1.2× 56 0.8× 83 1.3× 34 349
Paul Koller United States 9 163 1.3× 33 0.3× 117 1.5× 72 1.0× 43 0.7× 46 369
Esmée P. Hoefsmit Netherlands 9 188 1.5× 60 0.6× 72 0.9× 123 1.8× 97 1.5× 14 355
Anand Pathak United States 11 134 1.1× 41 0.4× 153 2.0× 37 0.5× 40 0.6× 25 395
Stephan Macher-Göppinger Germany 8 63 0.5× 31 0.3× 146 1.9× 54 0.8× 56 0.9× 16 311
Mahmut Celiker United States 8 114 0.9× 40 0.4× 118 1.6× 48 0.7× 29 0.5× 12 336
Hamid Ehsan United States 10 116 1.0× 34 0.4× 67 0.9× 31 0.4× 101 1.6× 46 341
Gaetano Saggio Italy 13 210 1.7× 86 0.9× 94 1.2× 71 1.0× 70 1.1× 28 468

Countries citing papers authored by Monali Vasekar

Since Specialization
Citations

This map shows the geographic impact of Monali Vasekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monali Vasekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monali Vasekar more than expected).

Fields of papers citing papers by Monali Vasekar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monali Vasekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monali Vasekar. The network helps show where Monali Vasekar may publish in the future.

Co-authorship network of co-authors of Monali Vasekar

This figure shows the co-authorship network connecting the top 25 collaborators of Monali Vasekar. A scholar is included among the top collaborators of Monali Vasekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monali Vasekar. Monali Vasekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rao, Pooja, Joel E. Segel, Kristin Bingen, et al.. (2025). The impact of a personal cancer diagnosis on adolescent and young adult cancer survivors’ social connectedness: A qualitative analysis. Journal of Health Psychology. 30(9). 2216–2231.
2.
Iyengar, Neil M., Joyce O’Shaughnessy, Heather Moore, et al.. (2025). Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion. npj Breast Cancer. 12(1). 16–16.
3.
Jones, G. Melvill, et al.. (2024). D-CRSE: Diminishing chemotherapy-related side effects through patient education, a mixed-methods pilot study. Journal of Psychosocial Oncology. 43(1). 1–15. 1 indexed citations
4.
Vasekar, Monali, et al.. (2023). Thoracic splenosis: an important consideration in oncology patients. BMJ Case Reports. 16(11). e257091–e257091.
5.
Gordon, Brett R., Ling Qiu, Shawna E. Doerksen, et al.. (2023). Addressing metastatic individuals everyday: Rationale and design of the nurse AMIE for Amazon Echo Show trial among metastatic breast cancer patients. Contemporary Clinical Trials Communications. 32. 101058–101058. 6 indexed citations
6.
Zhu, Junjia, Monali Vasekar, Cristina I. Truica, et al.. (2021). Group-led creative writing and behavioural health in cancer: a randomised clinical trial. BMJ Supportive & Palliative Care. 12(1). 91–98. 3 indexed citations
7.
Dodge, Daleela, et al.. (2020). Benefits of Surgical Treatment of Stage IV Breast Cancer for Patients With Known Hormone Receptor and HER2 Status. Annals of Surgical Oncology. 28(5). 2646–2658. 17 indexed citations
8.
Yin, Ming, Petros Grivas, Qi-En Wang, et al.. (2020). Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer. The Oncologist. 25(8). 680–688. 12 indexed citations
9.
Cai, Alice, et al.. (2020). EBV-Induced Pancytopenia: An Unusual Presentation of EBV Causing Bone Marrow Suppression - A Case Report. Pennsylvania Libraries: Research & Practice (University of Pittsburgh). 1.
10.
Vasekar, Monali, Edeanya Agbese, & Douglas Leslie. (2020). The value of immunotherapy: Comparison of annual cost per patient receiving immunotherapy versus chemotherapy in patients with non-small cell lung cancer.. Journal of Clinical Oncology. 38(15_suppl). e19364–e19364. 5 indexed citations
11.
O’Day, Elizabeth, Kim Leitzel, Suhail M. Ali, et al.. (2020). Abstract P4-10-25: Pretreatment serum metabolome predicts PFS in first-line trastuzumab-treated metastatic breast cancer. Cancer Research. 80(4_Supplement). P4–10. 7 indexed citations
12.
Hollenbeak, Christopher S., Matthew D. Taylor, Monali Vasekar, et al.. (2019). Postoperative chemotherapy and radiation improve survival following cardiac sarcoma resection. Journal of Thoracic and Cardiovascular Surgery. 161(1). 110–119.e4. 19 indexed citations
13.
Yin, Ming, Petros Grivas, Siraj M. Ali, et al.. (2018). Prognostic value of genomic alterations of DNA repair genes in advanced bladder cancer (ABC).. Journal of Clinical Oncology. 36(15_suppl). 4536–4536.
14.
15.
Vasekar, Monali, Syed Rizvi, Xin Liu, Kent E. Vrana, & Hong Zheng. (2016). Novel Immunotherapies for Hematological Malignancies. Current Molecular Pharmacology. 9(3). 264–271. 21 indexed citations
16.
Vasekar, Monali, David J. DeGraff, & Monika Joshi. (2016). Immunotherapy in Bladder Cancer. Current Molecular Pharmacology. 9(3). 242–251. 108 indexed citations
17.
Leitzel, Kim, Suhail M. Ali, Monali Vasekar, et al.. (2016). Serum collagen fragments and outcomes in hormone receptor-positive metastatic breast cancer.. Journal of Clinical Oncology. 34(15_suppl). 539–539. 1 indexed citations
18.
Vasekar, Monali. (2014). Targeted immunotherapy for non-small cell lung cancer. World Journal of Clinical Oncology. 5(2). 39–39. 6 indexed citations
19.
Vasekar, Monali, et al.. (2012). Emerging Molecular Therapies for the Treatment of Acute Lymphoblastic Leukemia. Advances in experimental medicine and biology. 779. 341–358. 2 indexed citations
20.
Vasekar, Monali & Timothy Craig. (2011). ACE Inhibitor–Induced Angioedema. Current Allergy and Asthma Reports. 12(1). 72–78. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoyuki Sasaki Breakdown of academic impact, for papers by Keiko Kagami Breakdown of academic impact, for papers by Kengo Nakahata Breakdown of academic impact, for papers by Paul Koller Breakdown of academic impact, for papers by Esmée P. Hoefsmit Breakdown of academic impact, for papers by Anand Pathak Breakdown of academic impact, for papers by Stephan Macher-Göppinger Breakdown of academic impact, for papers by Mahmut Celiker Breakdown of academic impact, for papers by Hamid Ehsan Breakdown of academic impact, for papers by Gaetano Saggio
Rankless by CCL
2026